IRB #

STUDY00019283

Title

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Principal Investigator

Christopher Ryan

Study Purpose

This study is being done to answer the following question:

Can the study drug, abexinostat, improve the effectiveness of pazopanib in treating renal cell carcinoma?

Medical Condition(s)

Locally Advanced or Metastatic Renal Cell Carcinoma

Eligibility Criteria

1. Age ≥ 18 years at the time of consent
2. Confirmed renal cell carcinoma with clear cell component
3. Locally advanced and unresectable or metastatic disease
4. Patients must not have had any prior VEGF tyrosine kinase inhibitor treatment
5. Up to 1 line of prior cytokine or immune checkpoint inhibitor treatment is allowed

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You will receive study drug as long as you are seeing clinical benefit.

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Xynomic Pharmaceuticals, Inc.

Recruitment End

11/30/2020

Compensation Provided

No


Go Back